Peer Review History
| Original SubmissionFebruary 19, 2020 |
|---|
|
PONE-D-20-04882 “It’s because I think too much”: Perspectives, experiences and opportunities for improvement among adults with hypertension engaged in HIV care in northern Tanzania PLOS ONE Dear Dr. Manavalan, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. We would appreciate receiving your revised manuscript by Jun 29 2020 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols Please include the following items when submitting your revised manuscript:
Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. We look forward to receiving your revised manuscript. Kind regards, Webster Mavhu Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Please include additional information regarding the interview guide used in the study and ensure that you have provided sufficient details that others could replicate the analyses. For instance, if you developed a guide as part of this study and it is not under a copyright more restrictive than CC-BY, please include a copy, in both the original language and English, as Supporting Information. 3. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. In your revised cover letter, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. We will update your Data Availability statement on your behalf to reflect the information you provide. Additional Editor Comments (if provided): • This paper could be more nuanced. A lot of described issues relate to what is known already about hypertension knowledge, attitudes and experiences. See for example: ‘Participants revealed multiple, intersecting challenges related to hypertension management including poor hypertension knowledge, insufficient hypertension counseling, financial constraints, lack of access to antihypertensive medications, staff shortages, HIV-related stigma, and lack of integration between hypertension and HIV care’. Just the last two themes specifically apply to people living with HIV - the rest are true for everyone else in this setting. The added value of this study is therefore not apparent. • This paper has the potential to highlight if and how experiences of individuals with both HIV & hypertension differ from those with just hypertension or even the general population and importantly how the care of these conditions could be improved especially as there is an opportunity to manage both at once. • Even for a qualitative study, the sample is too small. Authors state that this was guided by need to achieve theme saturation. It is unlikely that saturation was reached with just 13 in-depth interviews. Generally, 25-35 IDIs are considered acceptable for development of themes. See qualitative sampling recommendations in: Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. Feb 2006;18(1):59-82. Morse JM. Determining sample size. Qualitative Health Research. Jan 2000;10(1):3-5. • Also, if sampling was guided by the need to achieve theme saturation, how did authors determine they had reached theme saturation? Often, this is achieved by collecting initial interviews, reviewing emerging issues, collecting additional ones, reviewing again until no new themes emerge. As already stated, this process is rarely achieved after just 13 interviews. If researchers conducted 13 interviews due to pragmatic and other considerations, this should be stated. Otherwise, the data collection and analysis process leading to theme saturation should be fully described. • Themes could be more analytical than descriptive. For example ‘Poor understanding of the causes of hypertension’ could be a sub-theme of ‘Poor hypertension knowledge’ i.e. causes, mitigation etc. • The way the themes /sub-themes are presented is confusing. For example, ‘lifestyle factors’ is listed as a sub-theme of ‘Poor understanding of the causes of hypertension’. Should it be ‘lack of knowledge of lifestyle factors’? Even so, there is some contradiction on this theme as initially, it appears participants were unaware but lines 326-27 they mention some of the lifestyle measures they took to manage hypertension – suggesting they know the lifestyle factors. This is where a more analytical reflection would help. • Separately, “thinking too much” is an idiom of anxiety and depression in many African settings – it is possible this can lead to hypertension? • Still on themes, authors say they identified 10 themes and 11 sub-themes. Table 2 presents dominant themes – lists domains, 8 themes and 23 sub-themes? • Interview process is unclear. Did English-speaker interview together with Swahili RA with the RA interpreting every question and response? If so, probably explains length of interviews? • Setting is given as 1 of 2 clinics (abstract) and also 2 clinics (line 67). • Abstract should be structured as follows: Background, Methods, Results, Conclusions • Please attach interview guide [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: N/A Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: No Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: This paper demonstrates well the huge differences invested in treatment literacy for HIV opposed to hypertension, a gap that needs urgently addressing. As HIV cohorts age addressing these comorbidities is increasingly important and urgently need to invest in improving care. Overall the paper is well written and the thematics raised cover the important perceptions and barriers to accessing hypertension care for people living with HIV It’s because I think too much”: Perspectives, experiences and opportunities for improvement among adults with hypertension engaged in HIV care in northern Tanzania Would suggest edit to the title: Perspectives, experiences and opportunities for improvement in care of adults living with HIV and hypertension in northern Tanzania Lines 36-43 – in the introduction it would be useful to also include some reference to the prevalence and response if known in Tanzania to add to the broader statistics quoted. Line 58 – consider referencing these other studies looking at perceptions of hypertension in HIV cohort in SSA including from Tanzania – maybe highlight some key findings from these papers and can be developed further in discussion how authors findings compare Weiss JJ, Konstantinidis I, Boueilh A, et al. Illness Perceptions, Medication Beliefs, and Adherence to Antiretrovirals and Medications for Comorbidities in Adults With HIV Infection and Hypertension or Chronic Kidney Disease. J Acquir Immune Defic Syndr. 2016;73(4):403–410. doi:10.1097/QAI.0000000000001075 Hing M, Hoffman RM, Seleman J, Chibwana F, Kahn D, Moucheraud C. 'Blood pressure can kill you tomorrow, but HIV gives you time': illness perceptions and treatment experiences among Malawian individuals living with HIV and hypertension. Health Policy Plan. 2019;34(Supplement_2):ii36–ii44. doi:10.1093/heapol/czz112 Kagaruki GB, Mayige MT, Ngadaya ES, et al. Knowledge and perception on type2 diabetes and hypertension among HIV clients utilizing care and treatment services: a cross sectional study from Mbeya and Dar es Salaam regions in Tanzania. BMC Public Health. 2018;18(1):928. Published 2018 Jul 28. doi:10.1186/s12889-018-5639-7 Line 68 needs editing – maybe better to state number of patients in care at each facility. Some more detail on site choice would be helpful – were these tertiary , district or primary care facilities for example. Do the authors know in the chosen facilities who ( doctor or nurse) provides HIV and BP care. Is care integrated in the selected sites or we know up front that there are different clinics? Line 72: would suggest this reflects the criteria outlined in lines 77-79 re who eligible for recruitment Line 117 – don’t need to give range of age – just state median with the IQR Line 119 – median time HIV disease – do you mean the time from HIV positive diagnosis? Bit worrying such a big gap between the two Line 121- did the authors pick up where the hypertension diagnosis had been made if after the HIV diagnosis – in ART clinic- at another primary care clinic? Table 2: Listing lifestyle factors under poor understanding needs some explanation – were they not aware of diet , exercise etc Line 370: edit queue Line 373 : may be worth putting USD equivalent Line 417 – agree the importance of health education but would also add on the importance placed on engaging people living with HIV in their care and the role of peer support to strengthen treatment literacy – this point I feel is also missing within the conclusion as a key message Line 459/60 – the authors may also like to reference the recommendation on screening for cardiovascular disease within the WHO 2016 guidelines for antiretroviral care Do the authors know if there is a specific recommendation within the latest Tanzanian national guidelines for integration of ART and hypertension care - is the principle at least supported in national policy? In the discussion on integration and service delivery the authors may also like to consider adding whether using the principles of differentiated service delivery- which Tanzania has adopted for HIV within their operational manual – to enhance hypertension care. I believe there is guidance within that document recommending NCD /HIV integration, so to highlight if policies are supported versusu the challenges to fund and implement them Reviewer #2: This is a very well written, clear manuscript which discusses the experiences of people living with HIV and hypertension in Tanzania, and reflects upon the challenges of managing this ‘dual burden’ of disease. Integration is an important issue to consider, especially in contexts with high HIV/NCD prevalence and where there are significant differences in the provision of medication (eg ARVs being free but hypertensive treatment not). There are limitations to the paper which are acknowledged by the authors, and which mostly relate to the study design. As participants self-reported their diagnosis of hypertension, there may have been recall bias or uncertainty around this. There is also a very small sample size – this is a qualitative study, so a small sample is expected, but the authors rely on data from only 13 patients making me question how thorough the analysis could be. The perspectives of health-care providers are also missing, which would have been valuable in terms of making practical recommendations about how outcomes could be improved and understanding challenges from their perspective. Despite the limitations of the study design, the paper is well structured, the data well-presented and the discussion reflects upon many important, relevant issues to contexts within SSA, not just Tanzania. Title The manuscript focussed mostly on experiences and perspectives and it is unclear what the ‘opportunities for improvement’ are eg clinical outcomes, cardiovascular outcomes, HIV outcomes, improvement in psycho-social well being…? I suggest removing ‘opportunities for improvement’ from the title. The rest of the manuscript refers to perspectives and and experiences throughout, so I would edit the title to be in line with this. Abstract Overall, the abstract is well written. I would like to see some additional figures about HIV and hypertension prevalence in Tanzania if the word limit allows. Introduction Line 52 – write out twofold in full Line 53 – persons with HIV could be written in the standard PLWH which is used throughout Materials and methods The methods section is very clear and detailed. COREQ guidelines are not mentioned – was the checklist adhered to and submitted, as per journal requirements? Line 63 – as this is a qualitative paper, in line with other papers in the journal I suggest removing ‘materials’ as these are not relevant to this study Line 68 – why were these two clinics chosen? The abstract makes it sound like the study was conducted in ‘one of two’ clinics so I am unsure if it was one clinic, or both. Throughout the results, the clinics of the patients are not mentioned or linked with the quotes. Were there any differences between the two sites, or were they grouped together throughout rather than analysed separately? Line 73 – rather than recruitment being conducted until thematic saturation was reached, this should read ‘data collection was carried out until thematic saturation was reached’. Line 76 – who specifically were the HIV clinic and research staff? Was more than one person doing the recruitment at each site? A research assistant is mentioned later on, but it is unclear of how many different people were involved in the recruitment and data collection, and what their precise roles were. Line 78 – as mentioned by the authors, self-reported hypertension status is a limitation to the study. Would it have been possible to verify this through patient records? Line 90 – the PI is referred to as a physician throughout, without mentioning their role as a researcher, or research training (in line with COREQ guidelines). Was the physician also a qualitative researcher? There are also other details missing from COREQ here (eg gender of interviewer/assistant). Line 93 - I am very surprised that the interviews took so long as most of my interviews on similar issues do not take more than 30-45 minutes, so I would like to get some tips! Two hours is a very long time, especially when conducting interviews with people who – as the authors state – were often unsure of the treatment that they had received. Can the authors attach a copy of the interview guide in order to see the questions that were asked? As per COREQ guidelines, can you also state the mean duration and be more precise with interview length eg between 50 and 97 minutes. Line 94 – 3rd should be written in full Line 95 – at what point were the audio-recordings translated? Was the transcription and translation carried out simultaneously by the person transcribing? Line 105 and prior - as there is a such a small number of interviews, I would give the number that were verified rather than the percentage (or both) Line 114 - which language was the consent given in? Can the authors reflect upon the literacy levels in this population to explain why written rather than verbal consent was taken? This line should probably be rephrased to read ‘prior to data collection’ rather than ‘prior to enrolment’. Results Line 118 – I suggest rephrasing ‘no more than a primary school education’ – I understand what the authors mean here, but the phrasing is a little judgemental. Line 119 - would ‘median duration of HIV disease’ be ‘time since HIV diagnosis’ (see also table)? Is this information self-reported or from clinical records? (As an aside, if clinical records were consulted, was this mentioned in the consent, and who accessed them?) Line 124 – 8 should read eight Table two, line 135 onwards – are some of the phrases under the themes ‘in vivo’ codes from NVivo, written exactly as the interviewees spoke them? It would be helpful to point these out, especially as some of them look grammatically incorrect in the context of a table. I did not understand what ‘diagnosis in setting of symptoms’ meant -can you explain? It may be a clinical term I am unfamiliar with. Medications should be singular, not plural Overall, the data presented in the results in the form of quotes is well-written but I have some general comments on the presentation and introduction of the data. The quotes need more introduction eg ‘As explained by one of the interviewees below:’ or ‘As a 28 year old female interviewee stated:’ rather than just being listed. Not all the quotes link directly to the points being made prior to their introduction so some restructuring is required. There are also some spacing and formatting issues which make the quotes difficult to read, and as PLoS One does not do copy editing, it would be helpful to check the formatting and allow more space between the quotes and the body of the text. As there are a very small number of interviewees, I would prefer the authors to be more specific if they can. Whilst the aim of a qualitative paper is not to quantify responses (and I don’t want to suggest a full quantification of quotes at all), I feel in this case it would be beneficial to specify when it was only one participant, or all participants except for one etc rather than an over-reliance on many/few/some. Line 163 - again, I understand what the authors mean here but rather than stating ‘poor levels’, is there a less judgemental way of phrasing this? Limited understanding, or lower levels, for example. I would also question whether calling high blood pressure ‘presha’ implies a poor level of knowledge, as suggested in the previous sentence, or is simply a very common Sub-Saharan African way of referring to it and thus implies an understanding of the condition. Line 177 – this is interesting – can you provide more examples of those who talked about instantly dying or falling down? Line 184 - this is a very long sentence, and the interesting story gets lost! Can you revise it? Line 189 - should this be pharmacological treatment? Line 194 – how was ‘noise’ translated? Can you refer back to the transcript? I wonder if this is about literal noise, or about avoiding stress or chaotic situations rather than noisy environments… This is an interesting point which I would like to understand more. Line 181 – how many were many? I am interested to know how many used religious or traditional treatments. Line 151 – the quote does not link back to the previous statement about side-effects Line 159 – should this be a few/some participants, rather than ‘few’? Line 204 – how was this question asked? If it was a closed ended question, I could imagine most people would say yes to wanting additional information, but I am interested to know if people asked for extra information themselves, without prompting. Line 207 – my concern with this section is that not everyone was on treatment, thus there is a smaller sample interviewed here. Can the authors clarify at this point how many people were on treatment, and how big the sample is in reference to pill burden. Similarly, on line 212, how many participants from the sample were asked this question, as presumably it wasn’t asked to those who were on treatment (which I think is only one interviewee). Line 223 – this sentence is unclear to me. Do you mean challenges to adherence or interruption of treatment? Line 226 – the word committed is somewhat problematic. Someone could be committed to taking their HIV treatment, but still be unable to do so because of financial means, stigma, unable to get to the clinic etc. The commitment is still there, but they are unable to carry out the action. The following quote does not link to the point about being ‘committed’ so I suggest the authors re-order this section. Line 236 – the ‘setting of symptoms’ phrasing is unclear to me. Line 245 – including the age of this person would be helpful here – it is in the quote below, but could be moved up. The quote doesn’t mention the time period of several decades ago – can you include this to give more context? Line 249 – OPD can be left in full as it is only used once in the manuscript Line 257 – could this be rephrased as ‘challenges with provider communication and counselling’ ? Line 262 – cited rather than ‘did cite’ Line 264 – did this mean that they weren’t discussed regularly at follow up appointments, or that not all interviewees talked about monitoring? Line 272 – the below quote refers to arguments, rather than conflicts – did the longer audio-recording talk about more general conflict? Line 290 – rather than admitting reluctance, could this be rephrased to ‘were reluctant to use…’? Line 293 – the point about only being giving a prescription for 5-7 days is interesting, but could be more about practical reasons for not adhering to treatment (eg returning to the clinic weekly) than reluctance towards taking medication. Can the authors reflect on this? Line 300 – I appreciate that this is a person’s words, but it would be easier to read if the grammar were corrected eg the doctor told me, rather than have told me. As long as none of the meaning is lost, a ‘tidying up’ of quotes throughout the manuscript would help the readers. Line 308 – is the reference to ‘reduce their thinking’ a direct quote from someone? Is this referring to stress or something else? Line 315 – is traditional medicine man the term used locally, or does the more commonly used ‘traditional healer’ apply here? Line 327 – which sub- category of ‘most’ are being discussed here? How many of the sample were not already in care – is this the same as the one person currently on treatment? How was this question phrased (eg open or closed question, or participants offered this information without prompting)? Line 330 – this is a very programmatic turn of phrase which feels out of place in the results! (Although I completely agree with the point). ‘Participants reported that HIV and hypertensive care were managed separately…’ could be one possible rephrasing. Line 343 – can you provide more examples here? This is only one patient, but you state that many stated a preference… Line 374 -this paragraph feels more like an analysis/reflection for the discussion, rather than part of the results. Can you rewrite it, or move to the discussion? Discussion This is very nicely written and the results, literature and reflections are woven together well. The limitations are very fair and well-reflected upon by the authors. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step. |
| Revision 1 |
|
PONE-D-20-04882R1 “It’s because I think too much”: Perspectives and experiences of adults with hypertension engaged in HIV care in northern Tanzania PLOS ONE Dear Dr. Manavalan, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. 1. The paper has significantly improved. 2. The paper discusses a lot of general issues but could focus only on those related to PLHIV - paper could come down to 3,500 words. 3. Could also reduce quotes - maximum of two per point (and select the powerful ones). 4. Results could be re-arranged. 5. I am still struggling with some sections which mention lack of knowledge but later show participants had knowledge. Perhaps a more nuanced way of looking at this would be to say, 'When asked about what they were doing to reduce risk of hypertension, only 1 participant mentioned that they were taking less salt, fats, oil. However, when asked about the knowledge they had received from providers around this aspect, they mentioned several mitigation strategies, suggesting a mismatch between knowledge and practice' or something similar. 6. See additional suggestions in manuscript itself. Please submit your revised manuscript by Sep 24 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Webster Mavhu Academic Editor PLOS ONE Additional Editor Comments (if provided): 1. The paper has significantly improved. 2. The paper discusses a lot of general issues but could focus only on those related to PLHIV - paper could come down to 3,500 words. 3. Could also reduce quotes - maximum of two per point (and select the powerful ones). 4. Results could be re-arranged. 5. I am still struggling with some sections which mention lack of knowledge but later show participants had knowledge. Perhaps a more nuanced way of looking at this would be to say, 'When asked about what they were doing to reduce risk of hypertension, only 1 participant mentioned that they were taking less salt, fats, oil. However, when asked about the knowledge they had received from providers around this aspect, they mentioned several mitigation strategies, suggesting a mismatch between knowledge and practice' or something similar. 6. See additional suggestions in manuscript itself. [Note: HTML markup is below. Please do not edit.] [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.
|
| Revision 2 |
|
PONE-D-20-04882R2 “It’s because I think too much”: Perspectives and experiences of adults with hypertension engaged in HIV care in northern Tanzania PLOS ONE Dear Dr. Manavalan, Thank you for submitting your manuscript to PLOS ONE. We will accept the manuscript once the few suggested edits are addressed. Please submit your revised manuscript by Nov 16 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols We look forward to receiving your revised manuscript. Kind regards, Webster Mavhu Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.
|
| Revision 3 |
|
“It’s because I think too much”: Perspectives and experiences of adults with hypertension engaged in HIV care in northern Tanzania PONE-D-20-04882R3 Dear Dr. Manavalan, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Webster Mavhu Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: |
| Formally Accepted |
|
PONE-D-20-04882R3 “It’s because I think too much”: Perspectives and experiences of adults with hypertension engaged in HIV care in northern Tanzania Dear Dr. Manavalan: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Webster Mavhu Academic Editor PLOS ONE |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .